Surgery

Medicine and Dentistry

1. Abdominal Cancer 8%
2. Adenocarcinoma 10%
3. Adjuvant Chemotherapy 10%
4. Adjuvant Therapy 18%
5. Adverse Event 6%
6. Awareness 7%
7. Axillary Lymph Node 8%
8. Bevacizumab 10%
9. Biopsy Technique 15%
10. Bleeding 7%
11. BRCA1 14%
12. Breast Cancer 100%
13. Breast Reconstruction 7%
14. Cancer 49%
15. Cancer Surgery 10%
16. Cancer Therapy 8%
17. Carcinoma 10%
18. Cervical Cancer 15%
19. Chemoradiotherapy 20%
20. Chemotherapy 60%
21. Cisplatin 14%
22. Clinical Trial 9%
23. Colon Carcinoma 9%
24. Colorectal Carcinoma 15%
25. Computer Assisted Tomography 8%
26. COVID-19 7%
27. Cytoreductive Surgery 12%
28. Disease Free Survival 11%
29. Diseases 88%
30. Female Genital Tract Cancer 8%
31. Fluorouracil 9%
32. Folinic Acid 8%
33. Gynecological Oncology 20%
34. Hazard Ratio 13%
35. Histology 9%
36. Hormone Receptor 8%
37. Hormone Therapy 10%
38. Infusion 8%
39. Intraductal Carcinoma 14%
40. Intraperitoneal Chemotherapy 10%
41. Krukenberg Tumor 40%
42. Laparotomy 10%
43. Liver Metastasis 13%
44. Lung 10%
45. Lung Cancer 11%
46. Lymph Node 17%
47. Magnetic Resonance Imaging 6%
48. Malignant Neoplasm 73%
49. Mastectomy 17%
50. Median Follow Up 12%
51. Medicare 8%
52. Melanoma 29%
53. Mesothelioma 18%
54. Metastatic Carcinoma 18%
55. Minimal Residual Disease 8%
56. Morbidity 11%
57. Multivariate Analysis 7%
58. Neoadjuvant Chemotherapy 13%
59. Neoadjuvant Therapy 18%
60. Neoplasm 62%
61. Non Small Cell Lung Cancer 16%
62. Odds Ratio 10%
63. Oncologist 17%
64. Oncology 26%
65. Ovarian Cancer 64%
66. Overall Survival 51%
67. Paclitaxel 8%
68. Pancreas Adenocarcinoma 12%
69. Pancreas Cancer 14%
70. Pathologist 7%
71. Pelvis 17%
72. Phase II Trials 9%
73. Photochemotherapy 25%
74. Platinum 17%
75. Pleura Mesothelioma 26%
76. Pleurectomy 8%
77. Pneumonectomy 10%
78. Preoperative Radiotherapy 7%
79. Primary Tumor 10%
80. Prognostic Factor 8%
81. Progression Free Survival 10%
82. Quadrantectomy 9%
83. Quality Improvement 6%
84. Quality of Life 7%
85. Radiation Therapy 42%
86. Rectum Cancer 31%
87. Recurrent Disease 63%
88. Retroperitoneal Lymph Node Dissection 27%
89. Retroperitoneal Sarcoma 9%
90. Sentinel Lymph Node 7%
91. Sentinel Node 14%
92. Surgeon 31%
93. Surgery 19%
94. Surgical Oncology 8%
95. Symptomatic Treatment 11%
96. Systematic Review 7%
97. Systemic Therapy 12%
98. Treatment Option 7%
99. Tumor 36%
100. Uterine Cancer 11%